AbbVie Inc. SG&A Expenses

SG&A Expenses of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending December 30, 2020 was $3.23 Billion (a 13.53% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 90.62%
  • Annual SG&A Expenses for 2020 was $11.3 Billion (a 62.76% increase from previous year)
  • Annual SG&A Expenses for 2019 was $6.94 Billion (a -6.18% decrease from previous year)
  • Annual SG&A Expenses for 2018 was $7.4 Billion (a 17.54% increase from previous year)
  • Twelve month SG&A Expenses ending December 30, 2020 was $11.3 Billion (a 12.78% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses increased by 62.41% year-over-year
Trailing SG&A Expenses for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$11.3 Billion $10 Billion $8.83 Billion $6.96 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of AbbVie Inc.

Most recent SG&A Expensesof ABBV including historical data for past 10 years.

Interactive Chart of SG&A Expenses of AbbVie Inc.

AbbVie Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $3,231.0 $2,846.0 $3,527.0 $1,695.0 $11,299.0
2019 $1,951.0 $1,657.0 $1,654.0 $1,680.0 $6,942.0
2018 $1,929.0 $1,919.0 $1,760.0 $1,791.0 $7,399.0
2017 $1,956.0 $1,457.0 $1,509.0 $1,373.0 $6,295.0
2016 $1,679.0 $1,381.0 $1,466.0 $1,355.0 $5,881.0
2015 $1,737.0 $1,474.0 $1,703.0 $1,473.0 $6,387.0
2014 $3,341.0 $1,595.0 $1,448.0 $1,340.0 $7,724.0
2013 $1,448.0 $1,261.0 $1,406.0 $1,237.0 $5,352.0
2012 $1,411.0 $1,085.0 $1,246.0 $1,247.0 $4,989.0
2011 $4,716.09 $1,177.92 $5,894.0
2010 $3,820.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.